Developing an AI Pharmacy Chatbot for the Population of Hong Kong
The primary objective of this study is to is to develop a conversational AI service (chatbot) in Hong Kong to assist patients and caregivers with inquires related to Hospital Authority (HA)-prescribed medications, and to evaluate its effectiveness in answering medication-related questions. The main questions it aims to
| Condition(s) | Hyperglycaemia, Hypertension, Hyperlipidaemia, Artificial Intelligence (AI) |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | The primary objective of this study is to is to develop a conversational AI service (chatbot) in Hong Kong to assist patients and caregivers with inquires related to Hospital Authority (HA)-prescribed medications, and to evaluate its effectiveness in answering medication-related questions. The main questions it aims to answer are: 1. How satisfied are the patients and caregivers with this pharmacy chatbot? 2. How will the pharmacy chatbot impact eligible patients or caregivers on their (or the patient they are caring for) medication adherence, knowledge, and the consultation time with HA pharmacists? There will be an intervention group and a control group: 1. The intervention group will be invited to use the AI Pharmacy Chatbot online for 7 days through WhatsApp, a commonly used social med |
| Who can participate | Inclusion Criteria: * Patients aged 18 years or older diagnosed with either hyperglycaemia, hypertension, or hyperlipidaemia, and currently receiving medication prescribed by the Hospital Authority in Hong Kong. * Caregivers aged 18 years or older for patients described above. Exclusion Criteria: * There is no exclusion criterion, but they should meet the inclusion criteria above. |
| Ages | 18 Years |
| Sex | All |
| Accepts healthy volunteers | Yes |
| Lead sponsor | The University of Hong Kong |
| Locations | Hong Kong, Hong Kong; Hong Kong, Hong Kong |
| Start date | 2025-06 |
| NCT ID | NCT07037563 |
| Official listing | https://clinicaltrials.gov/study/NCT07037563 |